Neurocrine Biosciences
NBIX
699 hedge funds and large institutions have $13.2B invested in Neurocrine Biosciences in 2026 Q1 according to their latest regulatory filings, with 84 funds opening new positions, 306 increasing their positions, 216 reducing their positions, and 110 closing their positions.
42% more repeat investments, than reductions
Existing positions increased: 306 | Existing positions reduced: 216
0.29% more ownership
Funds ownership: 99.49% → 99.78% (+0.29%)
5% less funds holding
Funds holding: 732 → 699 (-33)
6% less capital invested
Capital invested by funds: $14.1B → $13.2B (-$886M)
20% less funds holding in top 10
Funds holding in top 10: 10 → 8 (-2)
24% less first-time investments, than exits
New positions opened: 84 | Existing positions closed: 110
43% less call options, than puts
Call options by funds: $39.1M | Put options by funds: $69M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$275M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$221M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$166M |
| 4 |
Millennium Management
New York
|
+$107M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$80.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$228M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$225M |
| 3 |
Los Angeles Capital Management
Los Angeles,
California
|
-$152M |
| 4 |
DM
Deerfield Management
New York
|
-$76.2M |
| 5 |
ZIG
Zurich Insurance Group
Zurich,
Switzerland
|
-$65.2M |
NBIX Hedge Fund Activity: Q1 2026 in Review
699 of the 8,030 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q1 2026, worth a combined $13.2B — down 6.3% from $14.1B a quarter earlier.
Sellers outnumbered buyers: 110 funds closed out of NBIX and 84 opened new positions — a net loss of 26 holders — while 216 trimmed existing stakes and 306 added.
The largest buyer was Two Sigma Investments, adding an estimated $275M. The largest seller was T. Rowe Price Associates, cutting an estimated $228M.
- 699 institutional investors held Neurocrine Biosciences (NBIX) as of Q1 2026, down from 732 in Q4 2025.
- Funds reported $13.2B of Neurocrine Biosciences stock for Q1 2026, down 6.3% quarter-over-quarter.
- 84 funds opened new Neurocrine Biosciences positions in Q1 2026 and 110 closed out, a net change of -26 holders.
- The largest Neurocrine Biosciences buyer in Q1 2026 was Two Sigma Investments, an estimated $275M added.
- The largest Neurocrine Biosciences seller in Q1 2026 was T. Rowe Price Associates, an estimated $228M sold.
Based on aggregated 13F filings for Q1 2026.